| Code | CSB-RA025141MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Bosakitug, targeting thymic stromal lymphopoietin (TSLP), a key epithelial-derived cytokine that plays a central role in initiating and amplifying type 2 inflammatory responses. TSLP is released by epithelial cells in response to allergens, pathogens, and tissue damage, where it activates dendritic cells and promotes the differentiation of naïve T cells toward a Th2 phenotype. Elevated TSLP expression has been implicated in multiple allergic and inflammatory conditions, including asthma, atopic dermatitis, chronic obstructive pulmonary disease, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyps, making it an important therapeutic target for type 2 inflammation.
Bosakitug is a human monoclonal antibody that specifically binds to TSLP, preventing its interaction with the TSLP receptor complex and thereby blocking downstream inflammatory signaling. This biosimilar antibody provides researchers with a valuable tool for investigating TSLP-mediated pathways, exploring mechanisms of allergic inflammation, and evaluating potential therapeutic interventions in preclinical models of type 2 inflammatory diseases.
There are currently no reviews for this product.